Curis, Inc. (CRIS)
$
2.1
-0.22 (-10.48%)
Key metrics
Financial statements
Free cash flow per share
-6.8153
Market cap
19.6 Million
Price to sales ratio
1.9147
Debt to equity
-0.3732
Current ratio
1.2225
Income quality
0.8902
Average inventory
0
ROE
-9.2475
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Curis, Inc., a biotechnology company focused on discovering and developing drug candidates for human cancers in the United States, reported selling, general, and administrative expenses of $18,647,000.00 indicating its operational overhead costs. The weighted average number of diluted shares outstanding is 5,293,294.00 reflecting potential dilution effects that could impact shareholder value. The net total of other income and expenses is $919,000.00 which showcases the company's non-core financial activities. The EBITDA is -$45,139,000.00 serving as a key indicator of the company's operational profitability, while the net income ratio is -4.73 reflecting the company's profitability margin. The clinical-stage pipeline features candidates such as Emavusertib, which is currently in a Phase 1/2 clinical trial targeting non-Hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes. Additionally, CI-8993, a monoclonal antibody, is designed to antagonize the V-domain Ig suppressor of T cell activation. Other notable candidates include Fimepinostat, CA-170, and CA-327, each targeting various oncology indications. Curis has established collaboration agreements with significant industry players, including F. Hoffmann-La Roche Ltd. and Genentech Inc. for the commercialization of Erivedge, and with Aurigene Discovery Technologies Limited to advance small molecule compounds in immuno-oncology and precision oncology. The stock is affordable at $2.20 making it suitable for budget-conscious investors. Additionally, the stock has a low average trading volume of 90,526.00 indicating lower market activity and possibly affecting liquidity. With a market capitalization of $17,780,616.00 the company is classified as a small-cap player within the financial landscape. Curis, Inc. is a key player in the biotechnology industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, where it drives innovation and growth. This combination of affordability, market positioning, and sector engagement highlights Curis, Inc.'s potential as it navigates the evolving landscape of cancer treatment and biotechnology development.
What is Curis, Inc. (CRIS)'s stock forecast?
Analysts predict Curis, Inc. stock to fluctuate between $2.10 (low) and $17.49 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Curis, Inc.'s market capitalization?
As of 2025-04-01, Curis, Inc.'s market cap is $17,780,616, based on 8,466,960 outstanding shares.
How does Curis, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Curis, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Curis, Inc. (CRIS) stock?
To buy Curis, Inc. (CRIS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CRIS. Place an order (Market, Limit, etc.).
What is the best time to invest in Curis, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Curis, Inc. perform in the last earnings report?
Revenue: $10,023,000 | EPS: -$8.96 | Growth: -30.65%.
Where can I find Curis, Inc.'s investor relations reports?
Visit https://www.curis.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Curis, Inc.?
You can explore historical data from here
What is the all-time high and low for Curis, Inc. stock?
All-time high: $348 (2021-05-12) | All-time low: $1.40 (2025-04-01).
What are the key trends affecting Curis, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
LEXINGTON, Mass. , March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and operating results on Monday, March 31, 2025, at 8:00 a.m.
prnewswire.com
LEXINGTON, Mass. , Dec. 10, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data from the TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting.
seekingalpha.com
Curis, Inc. (NASDAQ:CRIS ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Jonathan Zung - Chief Development Officer Conference Call Participants Ed White - H.C. Wainwright Billal Jahangiri - Truist Securities Daniel Bronder - Cantor Sean McCutcheon - Raymond James Operator Good morning, ladies and gentlemen, and welcome to the Curis Third Quarter 2024 Business Update Call.
zacks.com
Curis (CRIS) came out with a quarterly loss of $1.70 per share versus the Zacks Consensus Estimate of a loss of $1.88. This compares to loss of $2.13 per share a year ago.
prnewswire.com
Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.
prnewswire.com
LEXINGTON, Mass. , Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m.
prnewswire.com
LEXINGTON, Mass. , Oct. 29, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a combination of existing and new investors for the purchase of 2,398,414 shares of its common stock in a registered direct offering priced at-the-market under Nasdaq rules.
prnewswire.com
Symposium hosted by Eric S. Winer, MD, and Grzegorz S.
prnewswire.com
LEXINGTON, Mass. , Sept. 17, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference later today at 4:15 PM ET.
prnewswire.com
LEXINGTON, Mass. , Sept. 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The H.C.
See all news
